Solid Biosciences Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SOLID BIOSCIENCES INC. | ||
| Date: March 6, 2025 | By: | /s/ Alexander Cumbo |
|---|---|---|
| Alexander CumboPresident, Chief Executive Officer and Director(Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| /s/ Alexander Cumbo Alexander Cumbo | President, Chief Executive Officer and Director(Principal Executive Officer) | March 6, 2025 |
|---|---|---|
| /s/ Kevin Tan Kevin Tan | Chief Financial Officer(Principal Financial and Accounting Officer) | March 6, 2025 |
| /s/ Ian F. Smith Ian F. Smith | Executive Chairman of the Board | March 6, 2025 |
| /s/ Martin Freed Martin Freed | Director | March 6, 2025 |
| /s/ Ilan Ganot | Director | March 6, 2025 |
| Ilan Ganot | ||
| /s/ Clare Kahn | Director | March 6, 2025 |
| Clare Kahn | ||
| /s/ Georgia Keresty | Director | March 6, 2025 |
| Georgia Keresty | ||
| /s/ Sukumar Nagendran Sukumar Nagendran | Director | March 6, 2025 |
| /s/ Adam Stone Adam Stone | Director | March 6, 2025 |
| /s/ Lynne Sullivan Lynne Sullivan | Director | March 6, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.